跳至主要内容
临床试验/DRKS00019842
DRKS00019842招募中未知

Prospective, randomized controlled, single center study evaluating additional respiration therapy with a PEP trainer to prevent pneumonia in patients with higher neutropenic risk under chemotherapeutic treatment of an acute myeloic leukemia - NeutroRespCare

Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin0 个研究点目标入组 100 人开始时间: 2019年11月25日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Patient with AML under first-line high dose chemotherapy treated as in-patient under curative intention (OR patients under high dose chemotherapy with consecutive autologous stem cell transplantation - extended additional study population) .
  • 2. Informed consent

排除标准

  • 1. Patient with diagnosed pulmonary infection at study start.
  • 2. Patient with known primary immunodeficiency or uncontrolled HIV infection (Patients with known HIV infection but controlled disease, normal CD4 count and undetectable HIV virus load can participate).
  • 3. Patients with COPD GOLD III or IV or severe bronchial asthma.
  • 4. Patients with known infectious pulmonary disease.
  • 5. Patient unwilling or able to perform physio- and respiration therapy

研究者

发起方
Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin

相似试验